Last reviewed · How we verify
Meperon — Competitive Intelligence Brief
phase 2
moperone
D(4) dopamine receptor, D(2) dopamine receptor, D(3) dopamine receptor
Other
Small molecule
Live · refreshed every 30 min
Target snapshot
Meperon (MOPERONE). Moperone works by blocking the D(3) dopamine receptor, which is involved in regulating the brain's reward and motivation systems.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Meperon TARGET | MOPERONE | phase 2 | moperone | D(4) dopamine receptor, D(2) dopamine receptor, D(3) dopamine receptor |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (moperone class)
- · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Meperon CI watch — RSS
- Meperon CI watch — Atom
- Meperon CI watch — JSON
- Meperon alone — RSS
- Whole moperone class — RSS
Cite this brief
Drug Landscape (2026). Meperon — Competitive Intelligence Brief. https://druglandscape.com/ci/moperone. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing